SUPBIO

About SUPBIO

Guangzhou Supbio Biotechnology Co., Ltd. is a molecular biology diagnostics company founded in 2010 and headquartered in Guangzhou, China. The firm specializes in the industrialization of micro-precision detection technology geared towards the functional cure of major infectious diseases and tumors. It focuses on early diagnosis and efficacy evaluation, providing early screening services to patients.

Supbio develops, produces, and sells in-vitro diagnostic products and provides third-party in-vitro diagnostic services. Its core technology is the proprietary SUPBIO® patented micro-precision PCR technology. The company's product portfolio includes testing kits for HIV, HBV, TB, and various cancers. The kits are designed for early screening, efficacy evaluation, and diagnosis for treatment cessation. For example, its Human Immunodeficiency Virus Type I (HIV-1) DNA Detection Kit received NMPA approval in August 2024. Supbio also offers scientific research services, utilizing its nucleic acid detection and exosome separation technologies for partners in hospitals, disease control centers, universities, and research institutions.

The company's clients include hospitals, disease control organizations, research institutions, and individual patients, offering solutions that cover the entire process from screening and early diagnosis to treatment and monitoring. Supbio has received funding from investors including GGR Capital, Wonderland Capital, Beijing Prudential Capital Management, and Yanyuan Capital Group, completing a Series B round in July 2024.